Yuvraj

Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships

Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers...

Eisai Inc. Received U.S Food and Drug Administration for Eisai’s Halaven Injection

Eisai Inc. announced that the United States Food and Drug Administration (FDA) has approved Halaven™ (eribulin mesylate) Injection for the treatment of patients with...

Pfizer Inc, Study Shows Adding INSPRA to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure

Pfizer Inc. announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization...

MorphoSys Launches New Antibody Technology

MorphoSys AG has launched a novel antibody optimization platform called arYla. The company plans to use arYla to accelerate antibody optimization, with the goal...

Biomoda Selects Quintiles To Refine Lung Cancer Tests

Biomoda, Inc. has allied with Quintiles Global Central Laboratories to help refine the automated image recognition system for measuring the photon emission rate and...

Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development

Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will be discontinued and resources will be reallocated to other...

Forest Laboratories Enters Collaboration on Bystolic(R) and Savella(R)

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic(R)...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read